Hanson Wade Group have taken the decision to cancel this meeting.
Please do accept our apologies for any inconvenience or disappointment this will cause. Please register your interest here if you would like updates on the meeting or topic.
Accurately Targeting CNS Disorders by Innovating Gene Therapy Delivery Methods & Meeting Regulatory Requirements to Progress to Clinical Trials
The Gene Therapy for CNS Summit is the only industry-led conference dedicated to innovating and optimizing gene therapies for CNS disorders. With the changing regulatory landscape, the push to advance through the clinic and be first-in-class with innovative vector delivery methods, and the growing need to develop gene therapies for rare CNS disorders, there is an increasing demand to come together at this dedicated conference.
This summit equips you to streamline your gene therapy development and improve efficacy through in-depth content on:
- Optimizing AAVs, innovating capsids, and developing novel vectors to improve delivery to the brain
- Maximizing translational models to move from discovery to the clinic
- Improving CNS targeting and BBB crossing to reduce toxicities and enhance efficacy
- Streamlining manufacturing processes in early-stage development to prevent delays
- Analyzing different delivery devices to ensure successful gene therapy delivery
- Navigating IND submissions and regulatory guidance to ensure compliance
❝
I was able to learn about recent trends in addressing challenges in gene therapy, and I also had the opportunity to speak with professionals involved in this field.
Koichi Wada, Senior Scientist, Research, Mitsubishi Tanabe Pharma
❞
❝
The meeting was more intimate than usual, which facilitated meaningful conversations with attendees. The presentations were highly informative.
Ana Martini, Director, Business Development, Exothera
❞
Previously Attending Companies Include:
